Manganese‐Based Redox Homeostasis Disruptor for Inducing Intense Ferroptosis/Apoptosis Through xCT Inhibition And Oxidative Stress Injury
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202301453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Qi Dong und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Materials and Energy, Southwest University, Chongqing, 400715, China. Hauptthemen laut MEDLINE: Ferroptosis, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Intracellular redox homeostasis plays an important role in promoting tumor progression, development and even treatment resistance. To this end, redox balance impairment may become a prospective therapeutic target of cancer. Herein, a manganese‐based homeostasis modulator (MHS) is developed for inducing severe reactive oxygen species accumulation and glutathione (GSH) deprivation, where such redox dyshomeostasis brings about dramatic ferroptosis/apoptosis. Tumor‐specific degradation of manganese oxide nanocarriers contributes to hypoxia alleviation and loaded cargo release, resulting in apoptosis by augmented sonodynamic therapy and chemodynamic therapy. On the other hand, regional oxygenation significantly downregulates the expression of activating transcription factor 4, which can synergize with the released sulfasalazine to inhibit the downstream cystine antiporter xCT. Biosynthesis of GSH is sufficiently interrupted by the xCT suppression, leading to the reduction of glutathione peroxidase 4 (GPx4) level. The resultant excessive lipid peroxides promote intense ferroptosis to motivate cell death. On this basis, splendid treatment outcome by MHS is substantiated both in vitro and in vivo, thanks to the synergy of antitumor immunity elicitation. Taken together, this paradigm provides an insightful strategy to evoke drastic ferroptosis/apoptosis toward therapeutics and may also expand the eligibility of manganese‐derived nanoagents for medical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Materials and Energy, Southwest University, Chongqing, 400715, China.
- Cancer Center, Medical Research Institute, Southwest University, Chongqing, 400715, China.
- State Key Laboratory of Resource Insects, Southwest University, Chongqing, 400715, China.
ORCID-Profile: Peng Xue
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Dong, Q., Wang, J., Liu, J., Zhang, L., Xu, Z., Kang, Y., & Xue, P. (2023). Manganese‐Based Redox Homeostasis Disruptor for Inducing Intense Ferroptosis/Apoptosis Through xCT Inhibition And Oxidative Stress Injury. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202301453
Vancouver
Dong Q, Wang J, Liu J, Zhang L, Xu Z, Kang Y, et al. Manganese‐Based Redox Homeostasis Disruptor for Inducing Intense Ferroptosis/Apoptosis Through xCT Inhibition And Oxidative Stress Injury. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202301453
BibTeX
@article{Dong2023,
author = {Dong, Qi and Wang, Jie and Liu, Jiahui and Zhang, Lei and Xu, Zhigang and Kang, Yuejun and Xue, Peng},
title = {Manganese‐Based Redox Homeostasis Disruptor for Inducing Intense Ferroptosis/Apoptosis Through xCT Inhibition And Oxidative Stress Injury},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202301453}
}
EUVIMED